Skip to contentP
Perspective Therapeutics, Inc.
P
CATXPerspective Therapeutics, Inc. Q3 2015 · 10-Q
Revenue$1.16M$1.16M+2.1% vs Q3 2014 Net Income-$953.55K-$953.55KN/M vs Q3 2014 EPS Diluted-$0.02-$0.02N/M vs Q3 2014 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Perspective Therapeutics, Inc. · CIK 728387 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,134,839N/M Free Cash Flowderived-$1,164,145N/M Margins · derivedGross margin4.8%+0.3 pt vs Q3 2014
Operating margin-90.8%−3.6 pt vs Q3 2014
Net margin-82.3%+101.3 pt vs Q3 2014
ended Mar 31, 2015 · filed May 15, 2015 · 45 d after period end